In GBM, the benefit of Temozolomide is more pronounced in MGMT promoter methylated tumors20–23, and we found MGMT-methylated glioblastoma was predicted to be more sensitive to Temozolomide (p < 0.0001). This evidence concerns the gene MGMT and glioblastoma.